Comparison of the Osteoporosis Self-Assessment Tool for Asians and the fracture risk assessment tool - FRAX to identify densitometric defined osteoporosis: A discriminatory value analysis in a multi-ethnic female population in Southeast Asia.

Asia Assessment threshold FRAX OSTA Osteoporosis Screening

Journal

Osteoporosis and sarcopenia
ISSN: 2405-5263
Titre abrégé: Osteoporos Sarcopenia
Pays: Netherlands
ID NLM: 101666399

Informations de publication

Date de publication:
Jun 2020
Historique:
received: 16 02 2020
revised: 16 03 2020
accepted: 06 04 2020
entrez: 28 7 2020
pubmed: 28 7 2020
medline: 28 7 2020
Statut: ppublish

Résumé

The accuracy of FRAX® as a screening tool to identify osteoporosis and how it compares with tools such as Osteoporosis Self-Assessment Tool for Asians (OSTA), in Southeast Asian women has so far been unexplored. We aimed to determine the FRAX® thresholds that accurately identify densitometric osteoporosis and to compare its performance with that of OSTA for this purpose. Singaporean postmenopausal women (n = 1056) were evaluated. FRAX® Major Osteoporotic Fracture Probability (MOFP), Hip Fracture Probability (HFP) scores, and OSTA indices were calculated. Receiver operating characteristic (ROC) curves were constructed and via the Youden index, the optimal cut-off points of balanced sensitivity and specificity for dual energy X-ray absorptiometry (DXA)-defined osteoporosis were identified and the performance characteristics were compared. A FRAX® MOFP threshold of ≥3.7% had sensitivity, specificity, positive predictive value and negative predictive value of 0.78 (0.73-0.83), 0.63 (0.59-0.66), 0.4 (0.36-0.44), and 0.9 (0.87-0.92), respectively in identifying osteoporosis. The corresponding values for a HFP threshold of ≥0.6% were 0.85 (0.80-0.89), 0.58 (0.55-0.62), 0.39 (0.35-0.43), and 0.92 (0.9-0.94) and that for an OSTA index cut-off of ≤ -1.2 were 0.76 (0.70-0.81), 0.74 (0.71-0.77), 0.48 (0.43-0.54), and 0.91 (0.88-0.93). The area under the ROC curves were 82.8% (79.9%-85.6%), 77.6% (74.2%-81%), and 79.6% (76.5%-82.8%) for OSTA, MOFP, and HFP thresholds respectively. FRAX® and OSTA perform comparably in identifying osteoporosis in our population. OSTA has only 2 parameters and may be simpler to use. However, FRAX® may also have a role in primary screening to identify the postmenopausal woman to be referred for DXA scanning and may help facilitate fracture risk reduction discussions with the patient.

Identifiants

pubmed: 32715094
doi: 10.1016/j.afos.2020.04.001
pii: S2405-5255(20)30036-4
pmc: PMC7374549
doi:

Types de publication

Journal Article

Langues

eng

Pagination

53-58

Informations de copyright

© 2020 The Korean Society of Osteoporosis. Publishing services by Elsevier B.V.

Références

Singapore Med J. 1997 Jan;38(1):25-6
pubmed: 9269350
Osteoporos Int. 2014 Oct;25(10):2359-81
pubmed: 25182228
World Health Organ Tech Rep Ser. 1994;843:1-129
pubmed: 7941614
J Med Assoc Thai. 2007 Mar;90(3):420-5
pubmed: 17427514
Osteoporos Int. 2019 Apr;30(4):879-886
pubmed: 30671610
J Clin Endocrinol Metab. 2002 Apr;87(4):1586-92
pubmed: 11932287
Osteoporos Int. 2007 Aug;18(8):1033-46
pubmed: 17323110
J Clin Endocrinol Metab. 2000 Jan;85(1):231-6
pubmed: 10634392
Osteoporos Int. 2001;12(8):699-705
pubmed: 11580084
Arch Osteoporos. 2019 Nov 26;14(1):114
pubmed: 31773442
Arch Osteoporos. 2018 Nov 19;13(1):130
pubmed: 30456726
Value Health. 2004 Sep-Oct;7(5):518-28
pubmed: 15367247
Int J Epidemiol. 2018 Apr 1;47(2):389-390f
pubmed: 29415269
Cancer. 1950 Jan;3(1):32-5
pubmed: 15405679
JAMA. 2018 Jun 26;319(24):2521-2531
pubmed: 29946735
J Clin Densitom. 2014 Jan-Mar;17(1):32-7
pubmed: 23489972
J Bone Miner Res. 2014 Jul;29(7):1661-6
pubmed: 24431262
J Clin Densitom. 2018 Jan - Mar;21(1):119-124
pubmed: 28958825
Lancet. 2018 Feb 24;391(10122):741-747
pubmed: 29254858
Endocr Pract. 2016 Sep 2;22(Suppl 4):1-42
pubmed: 27662240
Osteoporos Int. 2012 Jan;23(1):391-7
pubmed: 21365460
BMC Bioinformatics. 2011 Mar 17;12:77
pubmed: 21414208
J Bone Miner Res. 1997 Sep;12(9):1471-9
pubmed: 9286764
Osteoporos Int. 2000;11(3):192-202
pubmed: 10824234
J Am Board Fam Med. 2016 Mar-Apr;29(2):233-9
pubmed: 26957380
J Med Assoc Thai. 2005 Oct;88 Suppl 5:S80-3
pubmed: 16871660
Osteoporos Int. 2018 Jul;29(7):1511-1513
pubmed: 29947864

Auteurs

Manju Chandran (M)

Osteoporosis and Bone Metabolism Unit, Department of Endocrinology, Singapore General Hospital, Singapore.

Yun Ann Chin (YA)

Department of Endocrinology, Singapore General Hospital, Singapore.

Kuan Swen Choo (KS)

Department of Endocrinology, Singapore General Hospital, Singapore.

Wan Chen Ang (WC)

Department of Dermatology, Changi Genera Hospital, Singapore.

Xiao Feng Huang (XF)

Osteoporosis and Bone Metabolism Unit, Department of Endocrinology, Singapore General Hospital, Singapore.

Xiao Ming Liu (XM)

Osteoporosis and Bone Metabolism Unit, Department of Endocrinology, Singapore General Hospital, Singapore.

Donovan Tay (D)

Division of Medicine, Sengkang General Hospital, Singapore.

Tin Kyaw Kyaw Aung (TKK)

Division of Medicine, Sengkang General Hospital, Singapore.

Amin Ali (A)

Division of Medicine, Sengkang General Hospital, Singapore.

Win Pa Pa Thu (WPP)

Department of Obstetrics and Gynaecology, National University Hospital, Singapore.

Susan Logan (S)

Department of Obstetrics and Gynaecology, National University Hospital, Singapore.

Sean Xuexian Yan (SX)

Department of Nuclear Medicine and Molecular Imaging, Singapore General Hospital, Singapore.

Sarath Lekamwasam (S)

Faculty of Medicine, University of Ruhuna, Galle, Sri Lanka.

Ying Hao (Y)

Health Services Research Unit (HSRU), Singapore General Hospital, Singapore.

Classifications MeSH